{"disease":{"id":"ivonescimab","name":"ivonescimab"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07021950","title":"AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":130,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07385001","title":"A Prospective, Multicenter, Phase Ib/II Trial of Ivonescimab (AK112) Combined With Albumin-Paclitaxel and Cisplatin as Neoadjuvant Therapy for ESCC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Tang-Du Hospital","has_results":false},{"nct_id":"NCT06940518","title":"Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}